Impact of the use of Extended™ Wear Infusion sets on metabolic, ultrasound, and psychological outcomes in adults with type 1 diabetes using the Medtronic MiniMed 780G: a pilot randomized controlled trial

Introduction

In people with type 1 diabetes (PwT1DM), insulin infusion sets (IIS) are often regarded as the most fragile componentof insulin pump therapy. Standard IISs should be replaced every 2–3 days to prevent site complications and hyperglycemia. The objectiveof this randomized controlled trial was to evaluate the impact of 7-day Extended™ Wear Infusion sets (EIS; Medtronic MiniMed,Northridge, CA, USA) on metabolic, ultrasound (USG), and psychological outcomes in PwT1DM treated with the MiniMed 780G system(MM780G, Medtronic MiniMed, Northridge, CA, USA). Material and methods: Fifteen participants in both the intervention (EIS) and control groups (standard IIS) completed the 3-month study.One participant in the control group did not attend the follow-up USG examination; however, all other clinical, continuous glucose monitoring(CGM), and questionnaire data were available and included in the analyses. In the intervention group, the mean age was 36.1 ± 10.7years, diabetes duration 20.3 ± 7.6 years, body mass index (BMI) 24.9 ± 4.0 kg/m², and glycated hemoglobin A1c (HbA1c) 6.7 ± 0.5%. There were no significant baseline differences between groups in age, diabetes duration, CGM indices, or HbA1c.